Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Efficacy and safety of immunotherapy combined with anti-vascular therapy and precision microbiota transplantation in the treatment of advanced colorectal cancer

ABSTRACT: Interventions: one:Efficacy and safety of nvolimab, lenvatinib mesylate combined with precision microbiota transplantation Primary outcome(s): Objective Response Rate (ORR) Study Design: Single arm

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 36430 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Gut microbiota transplantation in conventional mice

Project description:Gut microbiota dysbiosis characterizes systemic metabolic alteration, yet its causality is debated. To address this issue, we transplanted antibiotic-free conventional wild-type mice with either dysbiotic (“obese”) or eubiotic (“lean”) gut microbiota and fed them either a NC or a 72%HFD. We report that, on NC, obese gut microbiota transplantation reduces hepatic gluconeogenesis with decreased hepatic PEPCK activity, compared to non-transplanted mice. Of note, this phenotype is blunted in conventional NOD2KO mice. By contrast, lean microbiota transplantation did not affect hepatic gluconeogenesis. In addition, obese microbiota transplantation changed both gut microbiota and microbiome of recipient mice. Interestingly, hepatic gluconeogenesis, PEPCK and G6Pase activity were reduced even once mice transplanted with the obese gut microbiota were fed a 72%HFD, together with reduced fed glycaemia and adiposity compared to non-transplanted mice. Notably, changes in gut microbiota and microbiome induced by the transplantation were still detectable on 72%HFD. Finally, we report that obese gut microbiota transplantation may impact on hepatic metabolism and even prevent HFD-increased hepatic gluconeogenesis. Our findings may provide a new vision of gut microbiota dysbiosis, useful for a better understanding of the aetiology of metabolic diseases. all livers are from NC-fed mice only.

2017-03-16 | GSE81318 | GEO

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

Project description:The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD). The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.

| 2381286 | ecrin-mdr-crc

Impact of fecal microbiota transplantation (FMT) in 3 days-ABX-treated recipient mice using feces from 6 NSCLC patients at diagnosis.

Project description:This study aimed to analyze changes in gut microbiota composition in mice after transplantation of fecal microbiota (FMT, N = 6) from the feces of NSCLC patients by analyzing fecal content using 16S rRNA sequencing, 10 days after transplantation. Specific-pathogen-free (SPF) mice were used for each experiments (N=4) as controls.

2023-07-01 | E-MTAB-12812 | biostudies-arrayexpress

LC-MS metabolomics dataset from fecal microbiota transplantation experiments in a food allergy

Project description:Untargeted metabolomic analysis of serum and fecal samples was performed to investigate microbial metabolites associated with tolerance induction following fecal microbiota transplantation (FMT) in human subjects and microbiome-transplanted mice.

2026-03-10 | MSV000101091 | MassIVE

Fecal Microbiota Transplantation Alters Lung Transcriptome and Signaling Pathway

Project description:Rationale: Recent studies suggest a potential link between gut bacterial microbiota dysbiosis and PAH, but the exact role of gut microbial communities, including bacteria, archaea, and fungi, in PAH remains unclear. Objectives: To investigate the role of gut microbiota dysbiosis in idiopathic pulmonary arterial hypertension (IPAH) and to assess the therapeutic potential of fecal microbiota transplantation (FMT) in modulating PAH progression. Methods: Using shotgun metagenomics, we analyzed gut microbial communities in IPAH patients and healthy controls. FMT was performed to transfer gut microbiota from IPAH patients or MCT-PAH rats to normal rats and from healthy rats to MCT-PAH rats. Hemodynamic measurements, echocardiography, histological examination, metabolomic and RNA-seq analysis were conducted to evaluate the effects of FMT on PAH phenotypes. Measurements and Main Results: Gut microbiota analysis revealed significant alterations in the bacterial, archaeal, and fungal communities in IPAH patients compared to healthy controls. FMT from IPAH patients induced PAH phenotypes in recipient rats. Conversely, FMT from healthy rats to IPAH rats significantly ameliorated PAH symptoms, restored gut microbiota composition, and normalized serum metabolite profiles. Specific microbial species were identified with high diagnostic potential for IPAH, improving predictive performance beyond individual or combined microbial communities. Conclusions: This study establishes a causal link between gut microbiota dysbiosis and IPAH and demonstrates the therapeutic potential of FMT in reversing PAH phenotypes. The findings highlight the critical role of bacterial, archaeal, and fungal communities in PAH pathogenesis and suggest that modulation of the gut microbiome could be a promising treatment strategy for PAH.

2025-04-30 | GSE271297 | GEO

Fecal Microbiota Transplantation for Ulcerative Colitis.

Project description:Fecal Microbiota Transplantation for Ulcerative Colitis.

| PRJEB46777 | ENA

Fecal Microbiota Transplantation for Metabolic Syndrome

Project description:Fecal Microbiota Transplantation for Metabolic Syndrome

| PRJEB46778 | ENA

Autologous Fecal Microbiota Transplantation Restores the Infant Gut Microbiota and Metabolome After Antibiotics: a case report

Project description:This is an untargeted metabolomics dataset of the human gut metabolome derived from infant stool samples. Data acquisition was done using C18 negative and positive mode, as well as HILIC positive mode. In this case study there are 2 individuals, Baby 1 and Baby 2. Sample 1152 is pre-antibiotic sample of Baby 1, Sample 1162 is post-antibiotic without autologous fecal microbiota transplantation (aFMT). Sample 0036 is pre-antibiotic sample of Baby 2, and sample 0045 is post-antibiotic with post-aFMT treatment. The goal of this study was to determine if aFMT can restore the gut microbiota to the individuals pre-antibiotic state after exposure to antibiotics.

2026-03-08 | MSV000101070 | MassIVE

Washed Microbiota Transplantation for The Treatment of Oncotherapy-Related Intestinal Complications

Project description:Gut microbiota, known as "unrecognized organs", is closely related to the occurrence and development of tumors. Cancer is thought to occur secondary to local chronic inflammation. And some bacteria, such as Helicobacter pylori, also have direct genotoxicity, changing intracellular signaling pathways and thus causing abnormal cell growth. Systemic intestinal dysbiosis may lead to cancer, and fecal microbiota transplantation (FMT) can be a new weapon in anti-cancer treatment.Washed microbiota transplantation (WMT), a new stage of FMT, is based on the automatic microfiltration machine (GenFMTer, Nanjing, China) and the following repeated centrifugation plus suspension with support from specific facilities.we conducted a prospective, one-arm, open-label study on the efficacy and safety of WMT in the treatment of oncotherapy-related complications. This study aimed to exploring the therapeutic potential of WMT in the treatment of oncotherapy-related intestinal complications and improving the quality of life of patients.

| 2364793 | ecrin-mdr-crc

Fecal microbiota transplantation alleviates diabetes peripheral neuropathy

Project description:Fecal microbiota transplantation alleviates diabetes peripheral neuropathy

| PRJEB37479 | ENA